Since serum CCL22 levels represent disease activity in patients with early- and advanced-stage MF [12,25], and the production of CCL22 from TAMs is suppressed by topical 5% IQM in vivo (in a B16F10 mouse melanoma model) [22], the administration of topical 5% IQM may decrease serum CCL22 levels, leading to the suppression of tumor progression in patients with advanced-stage MF. The gene discussed is CCL22; the disease is melanoma.